Hartford Funding Administration Co. lessened its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 1.8% within the third quarter, in keeping with the corporate in its most up-to-date Type 13F submitting with the Securities and Change Fee (SEC). The agency owned 151,324 shares of the corporate’s inventory after promoting 2,698 shares through the quarter. Johnson & Johnson accounts for about 0.8% of Hartford Funding Administration Co.’s holdings, making the inventory its twentieth largest holding. Hartford Funding Administration Co.’s holdings in Johnson & Johnson had been price $24,524,000 as of its most up-to-date submitting with the Securities and Change Fee (SEC).
Different hedge funds additionally not too long ago purchased and offered shares of the corporate. Worth T Rowe Associates Inc. MD boosted its stake in shares of Johnson & Johnson by 16.8% within the first quarter. Worth T Rowe Associates Inc. MD now owns 21,834,359 shares of the corporate’s inventory valued at $3,453,978,000 after buying a further 3,139,499 shares through the interval. Massachusetts Monetary Providers Co. MA boosted its stake in shares of Johnson & Johnson by 10.8% within the second quarter. Massachusetts Monetary Providers Co. MA now owns 18,780,645 shares of the corporate’s inventory valued at $2,744,979,000 after buying a further 1,831,751 shares through the interval. Ameriprise Monetary Inc. boosted its stake in shares of Johnson & Johnson by 5.5% within the second quarter. Ameriprise Monetary Inc. now owns 14,374,397 shares of the corporate’s inventory valued at $2,100,427,000 after buying a further 754,200 shares through the interval. Dimensional Fund Advisors LP boosted its stake in shares of Johnson & Johnson by 16.2% within the second quarter. Dimensional Fund Advisors LP now owns 13,147,352 shares of the corporate’s inventory valued at $1,921,565,000 after buying a further 1,829,257 shares through the interval. Lastly, American Century Corporations Inc. boosted its stake in shares of Johnson & Johnson by 5.8% within the second quarter. American Century Corporations Inc. now owns 8,014,213 shares of the corporate’s inventory valued at $1,171,357,000 after buying a further 437,637 shares through the interval. Hedge funds and different institutional traders personal 69.55% of the corporate’s inventory.
Johnson & Johnson Inventory Up 1.5 %
JNJ inventory opened at $165.86 on Thursday. The corporate has a fifty day transferring common worth of $163.29 and a 200 day transferring common worth of $154.92. Johnson & Johnson has a 12 month low of $143.13 and a 12 month excessive of $168.85. The corporate has a market cap of $399.17 billion, a price-to-earnings ratio of 10.34, a price-to-earnings-growth ratio of two.65 and a beta of 0.52. The corporate has a debt-to-equity ratio of 0.44, a present ratio of 1.07 and a fast ratio of 0.85.
Johnson & Johnson (NYSE:JNJ – Get Free Report) final launched its quarterly earnings outcomes on Tuesday, October fifteenth. The corporate reported $2.42 EPS for the quarter, beating the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a internet margin of 46.34% and a return on fairness of 36.60%. The agency had income of $22.47 billion through the quarter, in comparison with the consensus estimate of $22.17 billion. Throughout the identical quarter within the prior 12 months, the agency earned $2.66 EPS. Johnson & Johnson’s income for the quarter was up 5.2% on a year-over-year foundation. Promote-side analysts count on that Johnson & Johnson will put up 10 earnings per share for the present 12 months.
Johnson & Johnson Dividend Announcement
The agency additionally not too long ago declared a quarterly dividend, which might be paid on Tuesday, December tenth. Buyers of file on Tuesday, November twenty sixth might be given a $1.24 dividend. The ex-dividend date is Tuesday, November twenty sixth. This represents a $4.96 annualized dividend and a yield of two.99%. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.
Analyst Upgrades and Downgrades
JNJ has been the subject of a number of analyst stories. Royal Financial institution of Canada raised their goal worth on shares of Johnson & Johnson from $178.00 to $181.00 and gave the corporate an “outperform” score in a report on Wednesday, October sixteenth. Citigroup raised their goal worth on shares of Johnson & Johnson from $180.00 to $185.00 and gave the corporate a “purchase” score in a report on Wednesday, October sixteenth. Cantor Fitzgerald reaffirmed an “chubby” score and issued a $215.00 goal worth on shares of Johnson & Johnson in a report on Wednesday, October sixteenth. Daiwa Capital Markets lower shares of Johnson & Johnson from an “outperform” score to a “impartial” score and lowered their goal worth for the corporate from $160.00 to $150.00 in a report on Tuesday, July twenty third. Lastly, StockNews.com raised shares of Johnson & Johnson from a “purchase” score to a “strong-buy” score in a report on Saturday, September 14th. Six analysts have rated the inventory with a maintain score, seven have given a purchase score and one has issued a robust purchase score to the corporate’s inventory. Based on MarketBeat, Johnson & Johnson has a consensus score of “Reasonable Purchase” and a median goal worth of $175.93.
Learn Our Newest Report on Johnson & Johnson
Insider Exercise at Johnson & Johnson
In different Johnson & Johnson information, VP Robert J. Decker offered 5,635 shares of the enterprise’s inventory in a transaction on Friday, August thirtieth. The shares had been offered at a median worth of $165.06, for a complete worth of $930,113.10. Following the transaction, the vp now instantly owns 18,973 shares of the corporate’s inventory, valued at roughly $3,131,683.38. The commerce was a 0.00 % lower of their place. The sale was disclosed in a submitting with the SEC, which may be accessed by means of the SEC web site. 0.16% of the inventory is owned by insiders.
Johnson & Johnson Profile
Johnson & Johnson, along with its subsidiaries, researches, develops, manufactures, and sells varied merchandise within the healthcare discipline worldwide. The corporate’s Modern Drugs section affords merchandise for varied therapeutic areas, akin to immunology, together with rheumatoid arthritis, psoriatic arthritis, inflammatory bowel illness, and psoriasis; infectious ailments comprising HIV/AIDS; neuroscience, consisting of temper issues, neurodegenerative issues, and schizophrenia; oncology, akin to prostate most cancers, hematologic malignancies, lung most cancers, and bladder most cancers; cardiovascular and metabolism, together with thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension by means of retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Learn Extra
Need to see what different hedge funds are holding JNJ? Go to HoldingsChannel.com to get the most recent 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Obtain Information & Scores for Johnson & Johnson Every day – Enter your e mail tackle beneath to obtain a concise every day abstract of the most recent information and analysts’ scores for Johnson & Johnson and associated corporations with MarketBeat.com’s FREE every day e mail publication.
